3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
CA 2438314 C · Owner: Sugen, Inc. · Inventors: Jin, Qingwu; Mauragis, Michael A.; Guan, Huiping
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to pyrrole substituted 2-indolinone compounds:, (see formula I), wherein R1 R2, R3, R4, R5, R6, R7 and Z are as defined herein and their , pharmaceutically acceptable salts which modulate the activity of protein kinases , and therefore are expected to be useful in the prevention or treatment of protein , kinase related cellular disorders such as cancer.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 15, 2002 and granted August 7, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 15, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 15, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.